This study aimed to compare the critical flicker frequency (CFF) and the mail-in cognitive function screening ınstrument (MCFSI) tests' effectiveness in diagnosing neurocognitive function losses in patients having severe obstructive sleep apnea syndrome (OSAS). A total of 85 subjects (47 patients with a diagnosis of severe OSAS and 38 healthy controls) were included into the study. MCFSI scores greater than or equal to five and CFF scores less than 39 Hz were considered abnormal. Demographic and polysomnographic parameters of patients with OSAS were studied, and correlations between the MCFSI, CFF scores and Epworth Sleepiness Scale (ESS) scores were analysed. The mean age of the patients was 49.6 AE 12.0 years. In the OSAS group, the CFF score was found to be low when compared with the control group, while the MCFSI score was found to be high. Pathological CFF scores (<39) were found in 13 patients (27.7%) in the OSAS group, while pathological MCFSI scores (≥5) were found in 19 patients (40.4%). CFF scores were found to be low in only 26% of the patients with OSAS who were found to have high MCFSI scores. MCFSI scores were high in only 38% of the patients with OSAS who were found to have low CFF scores. There was a significant correlation between ESS and CFF scores. In conclusion, the usefulness of the CFF test in determining cognitive function loss in patients with OSAS needs to be demonstrated via studies which utilize a larger sample size.
IN TROD UCTIO N
Obstructive sleep apnea syndrome (OSAS) is a common disorder that has a high prevalence in the general population; it is the most common sleep-related breathing disorder [American Academy of Sleep Medicine (AASM), 2014; Bade et al., 2014] . OSAS is associated with the cessation or reduction of airflow resulting from recurrent upper airway obstruction during sleep. While a person is sleeping, repeated partial or complete upper airway obstruction results in hypoxia/re-oxygenation and arousals (Turkish Thoracic Society, 2012) .
During the course of OSAS, complaints arise frequently due to neurocognitive function loss. These complaints include daytime sleepiness, tiredness, a decreased ability to make decisions, shortness of memory, dysmnesia, difficulty in concentrating and hypovigilance (Edwards et al., 2014) . These complaints cause accidents and workload loss for these patients. It is thought that the causes of neurocognitive function loss in patients with OSAS are cerebral hypoxia, the release of oxidative mediators, increased amounts of carbon dioxide, the activation of the sympathetic nervous system, changes in cerebral blood flow caused by endothelium dysfunction, comorbid illnesses such as Down syndrome and hormonal changes (Bucks et al., 2013; Lal et al., 2012) . In addition, other risk factors for OSAS such as age, gender, comorbid stroke, psychoactive drug use, smoking, alcohol dependence and obesity can influence neurocognitive function loss (Lal et al., 2012) . In studies conducted on patients with OSAS, the volume of grey matter which is associated with cognitive function has been found to decrease, especially in the left hippocampus, left posterior parietal cortex and right superior frontal gyrus (Canessa et al., 2011; Zimmerman and Aloia, 2006) .
The assessment of neurocognitive function loss requires complicated, expensive and time-consuming tests. As a result, tests in the form of questionnaires, which are simple and easy to administer, have been used more frequently to identify neurocognitive function loss; such tests include the mail-in cognitive function screening instrument (MCFSI) (Lal et al., 2015) . In the administration of these questionnaires, however, the effects of some of the clinical features of the patients (such as level of education, sociocultural features, travel history and age) decrease their reliability. Thus, more objective and functional tests are needed to evaluate neurocognitive function loss. One of the tests that is being used increasingly is the critical flicker frequency (CFF) test, also known as the vibration-free fusion frequency analysis. Some studies have shown that this test can be employed to identify early neurocognitive function loss, particularly in cases of hepatic encephalopathy (Kircheis et al., 2002) . However, few studies in the literature have considered the use of CFF in assessing cognitive function loss in OSAS (Schneider et al., 2004) .
The aim of our study was to investigate the role of the CFF test, which employs vibration-free fusion frequency analysis, in terms of its ability to evaluate neurocognitive function loss in patients with a diagnosis of severe OSAS.
MATERIAL AN D METH ODS Patients
A total of 85 cases, comprising 47 cases admitted to the Ondokuz Mayıs University Department of Chest Diseases Sleep Center with a first diagnosis of severe OSAS, and 38 healthy controls, were included into our study. Approval for this study was obtained from the ethics committee of Ondokuz Mayıs University Faculty of Medicine. The study was conducted according to the recommendations of the Declaration of Helsinki (sixth revision, 2008) . Written informed consent forms were obtained from all patients before they were included into the study. Patients who had diseases that affect cognitive function, and who were thus unable to complete the measurements, were excluded from the study. The exclusion criteria are represented in Table 1 . All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
The severity of the OSAS was evaluated using the apneahypopnea ındex (AHI), which was determined via standard overnight polysomnography. OSAS patients with an AHI greater than 30 were identified as having a severe condition, which is in accordance with the criteria of the American Academy of Sleep Medicine (Epstein et al., 2009 ). An MCFSI score greater than or equal to 5 was considered abnormal.
The MCFSI scores were evaluated according to methods described by Bade et al. (2014) (see Table 2 ). The Epworth Sleepiness Scale (ESS) was administered to all patients having OSAS (Johns, 1994) .
Critical flicker frequency measurement
All study patients underwent the CFF test via a HEPAtonorm analyser (Accelab GmbH, D-72127, Kusterdingen, Germany). Before CFF measurements were initiated, the testing procedure was repeated at least five times to ensure that the patient was sufficiently familiar with it. The CFF measurements were evaluated according to methods described by Lauridsen et al. (2011) . A pair of shield glasses was installed to protect the external light. Patients watched a red diode light that pulsed at a 1 : 1 ratio at a frequency of 60 Hz. At this high frequency, the red light was perceived as being fused. The light's pulse frequency was then decreased gradually until the light was perceived as flickering or pulsating. Patients were instructed to press a handgrip button when this occurred. The CFF measurement was performed nine times by the clinician, and the average of the measurements for each patient was calculated. CFF scores of less than 39 Hz were considered abnormal (Sharma et al., 2007) .
Statistical analysis
Data analysis was performed using SPSS statistical software (IBM SPSS statistics version 21.0; SPSS, Inc., Chicago, IL, USA). The data were presented as average AE standard deviation, mean (min-max) or number of cases (n, %) based on the test administered. The Kolmogorov-Smirnov test was used to assess whether the data showed normal distribution. The two-proportions test was used to compare two rates from independent groups. The CFF, MCFSI, ESS and AHI scores were compared using the Mann-Whitney U-test and independent-samples t-tests according to the distribution. Spearman's test was used for correlation analysis of data that were not distributed normally, while Pearson's correlation test was used for the correlation analysis of data that were distributed normally. An index of probability of less than 0.05 (P < 0.05) was considered significant.
RESUL TS
The average age of all the cases was 49.6 AE 12.0 years. Fifty-one cases (60.0%) were men, while 34 (40.0%) were women. The average body mass index (BMI) value of cases with OSAS was 33.9 AE 5.3, while the average AHI score of these cases was 49.9 AE 18.7. The average oxygen desaturation index (ODI) score was 55.9 AE 20.9, and the ESS median value was 8 (min-max; 0-15). Fourteen of the OSAS patients (29.8%) were smokers.
Thirteen cases (27.7%) in the OSAS group and four cases (10.5%) in the control group had a pathological CFF score (<39; P = 0.037). The CFF score was 41.27 AE 3.90 in the OSAS group and 42.9 AE 3.7 in the control group (P = 0.048; Fig. 1 ). According to the results of the MCFSI test, 19 cases (40.4%) in the OSAS group had a pathological cognitive function score (≥5), while eight cases (21.1%) in the control group had a pathological cognitive function score (P = 0.047). The median value of the MCFSI test was 4 (0-13) in the OSAS group and 2 (0-7.5) in the control group (P = 0.001; Fig. 2 ). The CFF score was found to be low in only 26% of the OSAS cases having a high MCFSI score. In contrast, in 38% of the OSAS cases with a low CFF score, the MCFSI score was found to be high. No significant correlation was found between the CFF and MCFSI scores in OSAS patients (r = -0.101, P = 0.524) and the control groups (r = 0.152, P = 0.368). The distribution of OSAS patients based on the MCFSI and CFF scores is presented in Table 3 .
In cases with OSAS, the CFF and MCFSI scores did not show any differences in terms of gender (P = 0.566 and P = 0.166). No significant difference was found between the CFF and MCFSI scores of smokers and non-smokers (P = 0.173 and P = 0.756).
Demographic and polysomnographic parameters of cases with OSAS and the correlation between the MCFSI, CFF scores and ESS scores were analysed. In these cases, the ESS scores were found to have a significant negative correlation only with the CFF scores (r = -0.376, P = 0.009). Table 4 shows the other correlation analysis results.
DISCUSSIO N
In our study, the MCFSI and CFF test scores in patients with OSAS were higher than those of the control groups. There was no correlation between these cognitive function tests. The ESS, which measures daytime sleepiness as an important sign of cognitive function loss, was found to be correlated significantly only with the CFF score.
In patients with OSAS, decreases in cognitive functions such as learning, memory, executive functions, vigilance, psychomotor performance and attention are observed frequently (Shpirer et al., 2012) . However, the pathogenesis and prevalence of this cognitive function disorder in OSAS are not understood clearly (Lal et al., 2012; Sforza and Roche, 2012) . In the pathogenesis of OSAS, neural damage caused by apnea recurrence, sleep fragmentation and nocturnal hypoxaemia is said to result in cognitive function loss (Sforza and Roche, 2012) . Experimental studies also support this hypothesis (Kalaria et al., 2004; Nair et al., 2011) . These factors, which are thought to play a role in the pathogenesis of OSAS, are thought to cause neural loss and cognitive function disorder in the hippocampus, anterior cingulate, cerebellum, parietal lobes and prefrontal cortex of the brain (Morrell et al., 2003; Sforza and Roche, 2012) .
Risk factors that are acknowledged to increase cognitive function disorder in patients with OSAS are comorbid genetic factors [Down syndrome, apolipoprotein E4 (ApoE4) positivity, high-risk craniofacial anatomy, etc.]; medical comorbidities (obesity, hypertension, hypothyroidism, cerebrovascular accidents, diabetes mellitus, congestive heart failure, etc.); behavioural and lifestyle factors (current cigarette smoking, alcoholism, etc.); increasing age; male gender; and use of psychoactive medications, including benzodiazepines, atypical antipsychotics and narcotics (Lal et al., 2012 (Lal et al., , 2015 Lim and Veasey, 2010) . In contrast to the literature (Bade et al., 2014; Lal et al., 2012 Lal et al., , 2015 Lim and Veasey, 2010) , no significant correlation was found between cognitive function tests and age, gender, BMI or smoking in our study.
In the literature, tests such as the Wechsler Adult Intelligence Scale Revised IQ tests, psychomotor vigilance test, steer clear performance test, finger tapping test and digit span test are used to assess cognitive function loss in people with OSAS (Lal et al., 2012) . Another of these tests is the MCFSI questionnaire, which is used frequently in the early diagnosis of Alzheimer's disease (Walsh et al., 2006) . Few studies in the literature have considered the use of the (Bade et al., 2014; Ferri et al., 2013; Lal et al., 2015) . Lal et al. (2015) assessed cognitive function loss using the MCFSI in 103 OSAS patients who did not receive continuous positive airway pressure (CPAP) treatment, and they examined the effect of the medications (including antidepressants, antipsychotics, anxiolytics, statins and narcotics) used in this function loss. In the present study, the mean percentage of rapid eye movement (REM) sleep and the ESS scores were found to be correlated with MCFSI scores. At the same time, decreased cognitive function and the use of antidepressants, antipsychotics, anxiolytics, statins and narcotics were shown to be correlated, and it was concluded that drug use as a risk factor had an effect on cognitive function loss in OSAS. In our study, unlike that of Lal et al., OSAS patients who used drugs that affected cognitive function were excluded from the study. Another study that used the MCFSI questionnaire to assess cognitive function in OSAS examined the comorbid effect of OSAS and the post-menopausal period on cognitive function loss (Lal et al., 2016) . This study found that cognitive function loss occurred in early post-menopausal women having high-risk OSAS. Unlike our study, this research did not exclude additional risk factors such as depression, stroke, alcohol consumption and recreational drug use, all of which increase cognitive function loss in patients with OSAS. With these additional risk factors, high-risk OSAS patients in the study were found to have significantly higher MCFSI scores compared to low-risk patients. In our study, the MCFSI values were similar to those of Lal et al.'s (2016) work, although most of the additional risk factors were excluded. In another study by Bade et al. (2014) , CPAP treatment was found to cause improvements in cognitive function in patients with OSAS, and the MCFSI scores of CPAP-compliant patients were found to be lower when compared with those of CPAP non-compliant patients. Cigarette smoking, psychoactive drug use, race and female gender were stated as risk factors resulting in high MCFSI scores. However, age, high AHI scores, obesity (BMI ≥ 30), the presence of metabolic syndrome, the presence of congestive heart failure and alcohol use did not correlate with elevated MCFSI scores. In contrast to the literature (Lal et al., 2015) , we found no clinical, demographic or polysomnographic findings that were correlated with the MCFSI score.
The CFF test is a psychophysiological test that is being used with increasing frequency; it is regarded as being objective, reproducible and sensitive in the early diagnosis of minimal hepatic encephalopathy, which presents with neurocognitive function loss as the initial finding (Wunsch et al., 2010) . This test is also said to have an important place in the early diagnosis of neurocognitive function losses, such as excessive daytime sleepiness and memory and concentration disturbance, caused by advanced hepatic encephalopathy (Torlot et al., 2013; Wunsch et al., 2010) . The CFF test has important advantages compared to other psychometric and neurophysiological tests used in the assessment of cognitive function loss. Some of these advantages include ease of implementation, low cost and characteristically not being affected by differences in patients' ages, languages or levels of education (Gencdal et al., 2014; Torlot et al., 2013; Wunsch et al., 2010) . However, few studies have employed the CFF test for patients with OSAS (Schneider et al., 2004; Schulz et al., 1997) . In a study of different patient groups exhibiting sleep disorders, Schneider et al. (2004) showed that narcoleptic patients and untreated OSAS patients had lower CFF scores when compared with the control group. In another study by Schulz et al. (1997) , it was concluded that CFF values differed over time in narcoleptic patients when compared with the control group, while they did not differ in patients with OSAS. In contrast to this study, our research did not assess the whole-day differences in CFF scores because measurements were not taken continuously. Only the averages of the repeated measurements were determined, and they were found to be significantly lower in patients with OSAS than in the control group.
There are cognitive function impairments in many areas, such as learning, memory, executive functions and vigilance in patients with OSAS. Currently, several tests are used to demonstrate the loss of cognitive function and to detect the different cognitive function areas. Thus, today, there is no gold standard for diagnosing or screening for cognitive impairment in OSAS. In addition to this, there are few data concerning the use of the CFF test to determine cognitive impairment in OSAS patients. Our study results showed that the MCFSI and CFF test scores were higher in OSAS patients than in the control groups; however, there was no correlation between both tests. This may have occurred for a variety of reasons, one of which may be the measurement of different cognitive function areas based on the different tests that were used. The MCFSI test measures memory and, to a limited degree, executive function, while the CFF test measures brain processing speed. Another reason may be the small sample size involved in this study.
In conclusion, it is necessary to gather more data using a greater number of study participants and to consider these factors when diagnosing cognitive function loss via the CFF test in OSAS patients.
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